Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up

Using intravenous thrombolysis for patients on new oral anticoagulants after a stroke

Official title: Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on New Oral Anticoagulants

Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06749834 · Data updated 2026-11-12

This study is testing if a common stroke treatment can safely help people who have recently taken new blood thinners after having a stroke.

More Acute Ischemic Stroke trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment280 (estimated)
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Academic / other
Locations2 sites (Hangzhou, Zhejiang and 1 other locations)
StatusRecruiting
StartedJanuary 27, 2025
Main results expectedDecember 31, 2026
Study endsJune 30, 2027
Registry record updatedFebruary 24, 2025
Trial IDNCT06749834 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older who have experienced acute ischemic stroke within 24 hours and have taken NOACs within the last 48 hours.

Probably not a fit

Patients who have contraindications for intravenous thrombolysis, such as a history of intracranial hemorrhage or severe head trauma, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study aims to evaluate the safety and efficacy of intravenous thrombolysis (IVT) in patients experiencing acute ischemic stroke (AIS) who have taken new oral anticoagulants (NOACs) within the last 48 hours. The study will recruit patients who meet specific inclusion criteria, including those with clinical signs of AIS and recent NOAC usage. The hypothesis is that IVT can improve neurological outcomes in these patients without significantly increasing the risk of severe bleeding complications. The findings could help redefine treatment guidelines for AIS patients on NOACs.

Why it matters

Potential benefit: If successful, this study could enable more patients on NOACs to receive effective treatment for acute ischemic stroke, potentially improving their recovery outcomes.

How similar studies have gone: While there is limited data on this specific approach, previous animal studies suggest that NOACs do not significantly increase the risk of hemorrhagic transformation, indicating potential for success in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with clinical signs of acute ischemic stroke within 24 hours of onset or awakening with stroke (if within 24 hours from the midpoint of sleep). Patients with AIS within 4.5-24 hours of onset must meet the IVT inclusion criteria specified in the guideline
2. Patients with new oral anticoagulants usage within 4-48 hours of onset;
3. Patients ≥ 18 years old
4. Informed consent has been obtained depending on local ethics requirements.

Exclusion Criteria:

1. Intended to proceed to endovascular treatment
2. With APTT \>40s
3. Pre-stroke mRS score \> 2
4. Contraindications for IVT:

1\) Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hematoma, etc.) 2) Previous history of intracranial hemorrhage 3) Severe head trauma or stroke history within the last 3 months 4) Intracranial tumors, giant intracranial aneurysms 5) Intracranial or spinal surgery within the recent 3 months 6) Major surgical procedures within the last 2 weeks 7) Gastrointestinal or urinary tract bleeding within the last 3 weeks 8) Active visceral bleeding 9) Aortic arch dissection 10) Arterial puncture in a site within the last 1 week that is not easy to compress and stop bleeding 11) Elevated blood pressure: Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg 12) Acute bleeding tendency, including platelet count \< 100 × 10⁹/L or other conditions 13) Received low-molecular-weight heparin treatment within 24 hours 14) Oral anticoagulants (warfarin) with INR \> 1.7 or PT \> 15 s 15) Blood sugar \< 2.8 or \> 22.22 mmol/L 16) Head CT or MRI indicates large-area infarction (infarction area ≥ 1/3 of the middle cerebral artery supply area) (4) The judgment is left to the discretion of the investigator

Where it's running

  • The First People's Hospital of Wenling
    Taizhou, Zhejiang, China
    Recruiting
  • Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou
    Hangzhou, Zhejiang, China
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.